These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29562224)

  • 21. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niraparib: First Global Approval.
    Scott LJ
    Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
    Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
    Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
    Rakowski JA; Ahmad S; Holloway RW
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer.
    Gnade C; McDonald ME
    Clin Obstet Gynecol; 2020 Mar; 63(1):86-91. PubMed ID: 31855903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 31. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Chan JK; Liang SY; Kapp DS; Chan JE; Herzog TJ; Coleman RL; Monk BJ; Richardson MT
    Gynecol Oncol; 2020 Dec; 159(3):604-606. PubMed ID: 32994055
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
    Arend R; Westin SN; Coleman RL
    Int J Gynecol Cancer; 2020 May; 30(5):684-694. PubMed ID: 32079709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rucaparib: A Review in Ovarian Cancer.
    Shirley M
    Target Oncol; 2019 Apr; 14(2):237-246. PubMed ID: 30830551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
    J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.